This work raises potential DCM treatment strategies that inhibit PDE4D isoforms with PDE4D-specific inhibitors or directly target the pathogenic PDE4D3 and PDE4D9 isoforms associated with SERCA2a in diabetic hearts. This evidence concerns the gene PDE4D and familial dilated cardiomyopathy.